Tislelizumab Versus Placebo Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Adjuvant Tislelizumab or Placebo for Locoregionally Advanced Nasopharyngeal Carcinoma: Interim Analysis of a Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined